Multi-Omics Approach Offers New Hope for Precision Treatment of Gallbladder Cancer

Gallbladder cancer is considered one of the most aggressive cancers of the biliary tract, with significant geographical variation, frequent late-stage diagnosis and poor survival outcomes. A recent narrative review suggests that a multi-omics approach could help overcome the limitations of conventional diagnostic and treatment strategies. By combining data from genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics, researchers can gain a broader understanding of the molecular mechanisms involved in tumour development, progression and treatment resistance.

The review found that integrating these molecular datasets could help identify important biomarkers, molecular subtypes and potential therapeutic targets, supporting precision oncology. Such approaches may contribute to earlier diagnosis, better patient classification, personalised treatment selection and improved disease monitoring. Researchers also highlighted the potential of multi-omics signatures in liquid biopsies and AI-based analysis of complex biological data. However, limited tissue samples, inadequate representation of gallbladder cancer in global datasets and a shortage of disease-specific clinical trials remain major challenges. The authors suggest that combining multi-omics technologies with AI, liquid biopsy methods and adaptive clinical trials could accelerate the development of personalised treatment strategies.